肝硬化患者肌少症的发生机制及诊疗进展  

Research progress of sarcopenia in patients with liver cirrhosis

作　　者：张兴会 郑梦瑶[1] 杨晋辉[1] ZHANG Xinghui;ZHENG Mengyao;YANG Jinhui(Department of Gastroenterology,The 2nd Affiliated Hospital of Kunming Medical University,Kunming 650101,China)

机构地区：[1]昆明医科大学第二附属医院消化内科,昆明650101

出　　处：《临床肝胆病杂志》2023年第9期2198-2204,共7页Journal of Clinical Hepatology

基　　金：国家自然科学基金(82160106)。

摘　　要：肌少症是一种因年龄增长导致肌肉进行性、广泛性下降的疾病。随着研究的深入,发现其与多种慢性病有关,其中在肝硬化患者中因蛋白质摄入减少、分解代谢失衡、自身合成不足等原因,发病率极高,与患者治疗效果、远期生存呈负相关,是肝硬化患者预后不良的独立危险因素。因此,积极干预肌少症对肝硬化患者具有重要的临床价值。本文从定义、诊断、发病机制、临床影响、治疗等方面综述肝硬化与肌少症之间的关系。Sarcopenia is a progressive and generalized muscle loss due to aging.With the deepening of research,it is found to be related to many chronic diseases.In patients with liver cirrhosis,owing to reduced protein intake,catabolism imbalance,insufficient self synthesis,and other reasons,the incidence of sarcopenia is extremely high,which negatively affects the treatment outcome and long-term survival,so it is an independent risk factor for poor prognosis in patients with liver cirrhosis.Therefore,it has important clinical value to manage sarcopenia in patients with liver cirrhosis.This review will explain the relationship between liver cirrhosis and sarcopenia from the aspects of definition,diagnosis,pathogenesis,clinical impact,and treatment.

关 键 词：肝硬化 肌减少症 诊断 

分 类 号：R575.2[医药卫生—消化系统] R685[医药卫生—内科学]